Takeda Pharmaceuticals Korea achieved a double win last year, seeing improvements in sales and operating income.

In particular, thanks to the growth of its anti-cancer drug portfolio, the company's sales exceeded the KRW 250 billion mark for the first time in 3 years since 2020, increasing sales growth for the second consecutive year.

In the long run, the key question will be whether the growth of products such as Obizur, which will be listed for reimbursement this year, can offset the decline in sales of Dexilant and Pantoloc.

Japanese pharmaceutical companies count the period from April 1 to March 31 as the first fiscal year, and the 16th fiscal year audited report, whi